Covid 19: ENSEMBLE: A Randomized, Double-Blind, Pacebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults Aged 18 Years and Older

Internal Medicine

Status	Active
Effective start/end date	9/25/20 → 5/5/25

Funding

Janssen Vaccines and Prevention BV: $11,725,844.00

1 Active

Covid 19: SCOPE: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults Aged 18 Years and Older
Greenberg, R. (PI), Caudill, T. (CoI), Kern, P. (CoI) & Simmons, C. (CoI)
Janssen Vaccines and Prevention BV
9/25/20 → 5/5/25
Project: Research project